

## Overview

### Useful For

Screening for mast cell activation disorders including systemic mastocytosis using random urine specimens

### Profile Information

| Test Id | Reporting Name                     | Available Separately | Always Performed |
|---------|------------------------------------|----------------------|------------------|
| R23BP   | 2,3-dinor<br>11B-Prostaglandin F2a | No                   | Yes              |
| CRETR   | Creatinine, Random, U              | No                   | Yes              |

### Highlights

2,3-Dinor-11beta-prostaglandin F2 alpha (2,3 BPG) is elevated in the urine of patients with systemic mastocytosis (SM).

This test should be used as a screening test for SM.

When 2,3 BPG is used in combination with urinary leukotriene E4 and N-methylhistamine, the sensitivity for SM detection increases to 90%.

### Method Name

R23BP: Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

CRETR: Enzymatic Colorimetric Assay

### NY State Available

Yes

## Specimen

### Specimen Type

Urine

### Ordering Guidance

Although a random urine collection is acceptable, the preferred specimen for 2,3-dinor-11beta-prostaglandin F2 alpha analysis is a 24-hour urine collection; order 23BPT / 2,3-Dinor 11 Beta-Prostaglandin F2 Alpha, 24 Hour, Urine.

If ordering this test with NMHR / N-Methylhistamine, Random, Urine, **both tests must be ordered under different order numbers**. They cannot share an order number.

### Specimen Required

**Patient Preparation:** Patients taking aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) may have decreased concentrations of prostaglandin F2 alpha. If medically feasible, for 2 weeks before specimen collection, patient should **not** take aspirin and for 72 hours before specimen collection, patient should **not** take NSAIDs.

**Supplies:** Sarstedt Aliquot Tube, 5 mL (T914)

**Container/Tube:** Plastic, 5-mL tube

**Specimen Volume:** 5 mL

**Collection Instructions:** Collect a random urine specimen.

**Specimen Minimum Volume**

3 mL

**Reject Due To**

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

**Specimen Stability Information**

| Specimen Type | Temperature              | Time    | Special Container |
|---------------|--------------------------|---------|-------------------|
| Urine         | Ambient                  | 8 hours |                   |
|               | Refrigerated (preferred) | 14 days |                   |
|               | Frozen                   | 30 days |                   |

**Clinical & Interpretive**

**Clinical Information**

2,3-Dinor-11beta-prostaglandin F2 alpha (2,3 BPG) is the most abundant metabolic product of prostaglandins released by activated mast cells. Systemic mastocytosis (SM) is a disease in which clonally derived mast cells accumulate in peripheral tissues. Degranulation of these mast cells releases large amounts of histamines, prostaglandins, leukotrienes, and tryptase.

The World Health Organization diagnostic criteria for SM require the presence of elevated mast cell counts on a bone marrow biopsy and one of the following minor criteria:

- Abnormal mast cell morphology
- KIT Asp816Val variant
- CD25-positive mast cells
- Serum tryptase greater than 20 ng/mL

Alternatively, SM diagnosis can be made with the presence of 3 minor criteria in the absence of abnormal bone marrow studies.

Measurement of mast cell mediators in blood or urine is less invasive and is advised for the initial evaluation of suspected cases. Elevated levels of serum tryptase, urinary N-methylhistamine, 2,3 BPG, or leukotriene E4 are consistent with the diagnosis of systemic mast cell disease.

---

**Reference Values**

<1802 pg/mg creatinine

**Interpretation**

Elevated urinary 2,3-dinor-11beta-prostaglandin F2 alpha (2,3 BPG) concentrations greater than 1820 pg/mg creatinine are consistent with the diagnosis of systemic mast cell disease when combined with clinical signs and symptoms. Pharmacological treatment with aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) has been shown to decrease production of 2,3 BPG.

Urinary 2,3 BPG has been shown to improve sensitivity in the screening of mastocytosis when used in conjunction with urinary leukotriene E4 and urinary N-methylhistamine. An internal study showed when all three urine markers are measured; sensitivity for systemic mastocytosis detection is 90%.

**Cautions**

Elevated levels of 2,3-dinor-11beta-prostaglandin F2 alpha (2,3 BPG) in urine are not specific for systemic mast cell disease and may be found in patients with angioedema, diffuse urticaria, or myeloproliferative diseases in the absence of diffuse mast cell proliferation.

Systemic mast cell disease is a heterogeneous disease, and some patients may not have elevated 2,3 BPG in urine.

Patients taking aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) may have decreased concentrations of prostaglandin F2 alpha if dosage has not been discontinued for 2 weeks or 72 hours, respectively.

**Clinical Reference**

1. Gotlib J, Pardanani A, Akin C, et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. *Blood*. 2013 Mar 28;121(13):2393-2401. doi: 10.1182/blood-2012-09-458521
2. Butterfield JH. Increased leukotriene E4 excretion in systemic mastocytosis. *Prostaglandins Other Lipid Mediat*. 2010 Jun;92(1-4):73-76. doi: 10.1016/j.prostaglandins.2010.03.003
3. Roberts LJ 2nd, Sweetman BJ, Lewis RA, Austen KF, Oates JA. Increased production of prostaglandin D2 in patients with systemic mastocytosis. *N Engl J Med*. 1980;303(24):1400-1404. doi:10.1056/NEJM198012113032405
4. Metcalfe DD. Mastocytosis syndromes. In: Middleton E Jr, Reed CE, Ellis EF, et al. eds. *Allergy Principles and Practice*. Vol II. 4th ed. Mosby Yearbook Inc; 1993:1537-1551
5. Butterfield J, Weiler CR. The utility of measuring urinary metabolites of mast cell mediators in systemic mastocytosis and mast cell activation syndrome. *J Allergy Clin Immunol Pract*. 2020;8(8):2533-2541

**Performance****Method Description**

2,3-Dinor-11beta-prostaglandin F2 alpha (2,3 BPG) is quantified in urine by liquid chromatography tandem mass spectrometry (LC-MS/MS). Deuterium-labeled 2,3-dinor-11beta-prostaglandin F2 alpha (d9-2,3 BPG) and reagent are added to all controls and specimens, which are then liquid/liquid extracted. The extractant is evaporated and samples and controls then reconstituted. Chromatographic separation is achieved with an analytical column. This eluent is

---

transferred to an API 5000 MS/MS. The ratios of the integrated peak heights of 2,3 BPG and d9-2,3 BPG internal standard are used to calculate the concentration of the analyte. All 2,3 BPG concentrations are normalized to urine creatinine levels.(Unpublished Mayo method)

**Creatinine:**

All 2,3 BPG concentrations are normalized to urine creatinine levels measured using a Roche cobas enzymatic method. The enzymatic method is based on the determination of sarcosine from creatinine with the aid of creatininase, creatinase, and sarcosine oxidase. The liberated hydrogen peroxide is measured via a modified Trinder reaction using a colorimetric indicator. Optimization of the buffer system and the colorimetric indicator enables the creatinine concentration to be quantified both precisely and specifically.(Package insert: Creatinine plus ver 2. Roche Diagnostics; V15.0, 03/2019)

**PDF Report**

No

**Day(s) Performed**

Tuesday, Thursday

**Report Available**

3 to 8 days

**Specimen Retention Time**

14 days

**Performing Laboratory Location**

Rochester

**Fees & Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

84150

82570

**LOINC® Information**

## Test Definition: 23BPR

2,3-Dinor 11 Beta-Prostaglandin F2 Alpha,  
Random, Urine

| Test ID | Test Order Name                    | Order LOINC® Value |
|---------|------------------------------------|--------------------|
| 23BPR   | 2,3-dinor 11B-Prostaglandin F2a,RU | 97658-9            |

| Result ID | Test Result Name                | Result LOINC® Value |
|-----------|---------------------------------|---------------------|
| CRETR     | Creatinine, Random, U           | 2161-8              |
| 603459    | 2,3-dinor 11B-Prostaglandin F2a | 97658-9             |